STAT+: FDA staff reiterate concerns about Replimune skin cancer treatment

STAT PlusBiotech FDA staff reiterate concerns about Replimune skin cancer treatment Advisory committee set to review treatment at center of heated debate over agency standards Manage alerts for this article Email this article Share this article By Elaine Chen and Matthew HerperJuly 28, 2026 Elaine Chen[email protected]Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.Matthew Herper[email protected]Matthew Herper covers medical innovation — both its promise and its perils.

Regulators at the Food and Drug Administration have reiterated concerns that Replimune does not have adequate data to support an approval of its investigational skin cancer treatment, as the biotech tries for the third time to seek clearance for its highly controversial drug. In briefing documents released Tuesday ahead of a meeting of FDA advisers later this week, the agency took issue with the single-arm trial the biotech relies on, in which patients who have already tried a PD-1-inhibitor took Replimune’s drug, called RP1, in combination with the PD-1-inhibitor Opdivo. The agency argued the study is not enough to properly evaluate the efficacy of the drug itself and whether the treatment, which is injected locally, has systemic benefits.Advertisement Replimune counters in its own briefing document that “it is not feasible or ethical” to conduct a study that randomly assigns its drug or placebo on top of PD-1 inhibitors in patients whose cancer has stopped responding to PD-1s, since “there is no evidence that continued anti-PD-1 monotherapy provides any level of clinical benefit” to those patients.

STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account?

Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+.

Subscribe Log In biotechnology, Cancer, drug development, Pharmaceuticals, STAT+ Submit a correction requestReprints Elaine Chen National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

Matthew Herper Senior Writer, Medicine, Editorial Director of Events Matthew Herper covers medical innovation — both its promise and its perils. Newsletter All the health and medical news you need today, in one email Recommended Biotech July 28, 2026 STAT Plus: Preliminary trial results suggest a path to a safer Alzheimer’s treatment Health July 28, 2026 STAT Plus: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD Advertisement Health Care Inc. Newsletter July 27, 2026 STAT Plus: Pharma’s drug spending deflection Biotech July 27, 2026 STAT Plus: Sarepta names Michael Severino, former Tessera CEO, as new chief executive Biotech July 27, 2026 STAT Plus: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug Subscriber Picks